YWYuanhao Wu

Yuanhao Wu

*This is an algorithmically generated author record based on publicly available information.

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuanhao Wu has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Chen Li

    Department of Dermatology The First Affiliated Hospital (Shenzhen People's Hospital) School of Medicine Southern University of Science and Technology Shenzhen China

    5 shared publications
  • Bin Xue

    Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China

    4 shared publications
  • Xiao-Ya Liu

    Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China

    4 shared publications
  • Bin Liu

    Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China

    3 shared publications
  • Lei Zhang

    Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China

    3 shared publications
  • Wei Liu

    Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China

    3 shared publications

Latest Publications

  • Open Access

    Wilforine attenuates inflammatory osteolysis by suppressing osteoclast fusion through JAK-STAT-stomatin immunoregulatory signaling

    by Shaohui Geng, Yiwei Guan, Zi Ye, Dongdong Zhao, Yijin Jiang, Jingyuan Fu, Han Sheng, Shuhan Yang, Hongxu Liu, Fuwen Deng, et al.

    Background: Excessive osteoclast fusion and activation are central drivers of bone erosion in inflammatory osteopathies, which are closely linked to immune dysregulation. Wilforine, a natural compound, exhibits immunomodulatory and therapeutic potential, yet its precise mechanism of action—particularly its influence on the osteoclast membrane microenvironment and associated immune signaling—remains incompletely understood. Methods: We employed a multi-level strategy combining in vivo and in vitro functional validation with systematic multi-omics analysis. The in vivo efficacy of Wilforine was assessed in a Pstpip2 cmo mouse model via Micro−CT and histopathology. In vitro studies utilized osteoclast culture, TRAP staining, scanning electron microscopy, and immunofluorescence to evaluate cell fusion and protein localization. Preliminary target prediction was conducted using network pharmacology. The core mechanism was elucidated through integrated proteomics and transcriptomics, followed by targeted functional validation including β−cyclodextrin−mediated lipid raft disruption and immune−related pathway analysis. Results: Wilforine significantly alleviated bone erosion, marrow edema, and inflammatory infiltration in vivo , and potently inhibited osteoclast multinucleation in vitro . Multi-omics profiling revealed that Wilforine broadly reversed disease-associated dysregulation, specifically upregulating cholesterol metabolism and glycosphingolipid biosynthesis pathways while modulating key immune-inflammatory networks such as NF−κB. This systemic remodeling of the lipid metabolic landscape was functionally linked to the disruption of membrane lipid raft integrity—critical platforms for immune receptor signaling. Consequently, the raft-dependent localization and function of key fusion proteins (CD9, DC−STAMP) were impaired. Mechanistically, Wilforine exerted these effects by suppressing the JAK−STAT signaling pathway, a central regulator of immune and inflammatory responses, leading to the downregulation of the essential lipid raft scaffold protein Stomatin. Conclusion: This study defines a novel immunometabolic mechanism wherein Wilforine inhibits osteoclast fusion and bone resorption by reprogramming cellular lipid metabolism and disrupting the “JAK−STAT – Stomatin – Lipid Raft” functional axis. It highlights lipid rafts as a viable immunomodulatory microenvironment in bone disorders and provides a strong multi−omics−supported rationale for developing Wilforine as a bone−targeted immunotherapeutic agent.


  • Open Access

    Dose-dependent immunotoxic mechanisms of celastrol via modulation of the PI3K-Akt signaling pathway

    by Shaohui Geng, Jingqi Wen, Chunli Shen, Li Liu, Yijin Jiang, Jingyuan Fu, Yiwei Guan, Zi Ye, Yuanhao Wu, Chen Li, et al.

    Ethnopharmacological relevance: Celastrol, a bioactive compound from Tripterygium wilfordii Hook.f., is known for its anti-inflammatory and immunomodulatory effects, but its immunotoxicity is underexplored. This study investigates the mechanisms of celastrol-induced immunotoxicity, focusing on the PI3K-Akt signaling pathway, a key regulator of immune function.Materials and methods: An integrative approach combining network toxicology, molecular docking, and experimental biology identified molecular targets in celastrol-induced immune dysfunction. Network toxicology mapped key pathways, and molecular docking predicted interactions with immune-related proteins. High-dose celastrol (10 mg/kg) was administered to C57BL/6J mice, followed by a histopathological analysis of the thymus and spleen. RNA-Seq evaluated gene expression in immune pathways, and IHC/mIHC validated PI3K-Akt signaling pathway protein expression.Results: Network toxicology identified the PI3K-Akt signaling pathway as a key target of celastrol’s immunotoxic effects. High-dose celastrol caused histopathological damage in the thymus and spleen, including lymphocyte depletion and immune cell infiltration. RNA-Seq showed upregulation of critical genes in the PI3K-Akt signaling pathway (Egfr, Pik3c, Akt3), linked to cell proliferation and survival. IHC confirmed increased expression of EGFR, AKT, PIK3, and mTOR, with decreased PTEN. mIHC revealed elevated macrophage activation and inflammation. In contrast, low-dose celastrol suppressed PI3K-Akt signaling by downregulating mTOR, indicating dose-dependent modulation of immune function.Conclusion: Our study demonstrates the dose-dependent immunotoxic effects of celastrol, which is toxic in high doses caused by activation of the PI3K-Akt signaling pathway, while low doses offer protection by blocking this signaling pathway. These findings emphasize the importance of dose selection in therapeutic and safety contexts, enhancing understanding of celastrol’s biological effects and its clinical potential in immune-related diseases.


  • Open Access

    Therapeutic approaches for SAPHO syndrome from the perspective of pathogenesis: a review of the literature

    by Yunuo Wang, Mengjiao Gu, Zixiang Zheng, Haixu Jiang, Luyao Han, Hanjing Huang, Yuanhao Wu, Chen Li

    Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome is a rare autoinflammatory disease characterized by cutaneous manifestations and osteoarticular damage. The pathogenesis of SAPHO syndrome has not yet been elucidated, but studies have shown that the abnormal bone metabolism of patients with SAPHO syndrome is most likely due to localized infections that induce immune disorders in the body. Although no standardized treatment protocols exist, based on existing case studies and data from open studies, we propose that the treatment of SAPHO syndrome can be categorized into three areas according to the symptomatic manifestations of the disease: (1) control of focal infections using antibiotics and tonsillectomy; (2) administration of DMARDs to manage disease progression; and (3) bone remodeling therapy with bisphosphonates to address abnormal bone metabolism. Furthermore, a comprehensive treatment approach tailored to the clinical manifestations of the patient can effectively alleviate symptoms and enhance quality of life.


  • Open Access

    Familial clustering of SAPHO syndrome

    by Mengjiao Gu, Zixiang Zheng, Chen Zhang, Yuru Zhang, Yuanhao Wu, Chen Li

    In a novel investigation of familial aggregation in SAPHO syndrome, a rare chronic autoinflammatory disorder characterized by the acronym synovitis, acne, pustulosis, hyperostosis, and osteitis, we identified a unique familial cohort with four affected individuals, including a male, marking the first report of male familial involvement in the literature. The index case manifested palmoplantar pustulosis, which was succeeded by symptoms of anterior chest wall and upper limb pain, culminating in a diagnosis of SAPHO syndrome following a 99mTc-MDP whole-body bone scintigraphy. Subsequently, three maternal aunts of the index case exhibited analogous clinical presentations, leading to a SAPHO syndrome diagnosis. All affected family members reported anterior chest wall pain, with three demonstrating peripheral joint involvement and one exhibiting spinal manifestations. Furthermore, three individuals developed palmoplantar pustulosis, while one lacked cutaneous manifestations. The study also delved into the genetic underpinnings of SAPHO syndrome, identifying potential associations with specific genetic variants, although no genetic sequencing was conducted in this report. Future studies are warranted to perform genetic analyses that may elucidate novel pathogenic genes, thereby enhancing our understanding of the disease's etiology and potentially informing therapeutic strategies.

  • Open Access

    Coexistence of adult-onset Still’s disease and SAPHO syndrome

    by Yunuo Wang, Haixu Jiang, Xinbo Yu, Qiuwei Peng, Zixiang Zheng, Yuanhao Wu, Chen Li


  • Open Access

    Molecular mechanism of reproductive toxicity induced by Tripterygium Wilfordii based on network pharmacology

    by Qing Ding, Yuanhao Wu, Wei Liu

    To explore the possible molecular mechanism of reproductive toxicity of Tripterygium wilfordii from the perspective of network pharmacology and bioinformatics. The compounds of T wilfordii were obtained by querying the relevant Chinese medicine database, the effective compounds were screened and the corresponding targets were obtained, and then compared with the reproductive toxicities related to disease targets obtained from the disease gene database to infer the potential toxic targets of reproductive toxicity of T wilfordii. Then, the key targets of reproductive toxicity of T wilfordii were screened using Search Tool for the Retrieval of Interacting Genes/Protein and Cytoscape. The gene ontology function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, as well as module analysis, were performed on the key targets using Database for Annotation, Visualization, and Integrated Discovery and Cytoscape, respectively. Finally, the network between effective compounds-toxic targets was conducted to see how the compounds interacted. A total of 48 effective compounds and 482 potential toxic targets related to the reproductive toxicity of T wilfordii were screened. The enrichment analysis results showed that the key targets were mainly enriched in biological processes such as response to drug, ionotropic glutamate receptor signaling pathway, and KEGG pathways such as neuroactive ligand-receptor interaction, cAMP signaling pathway. In the protein-protein interaction network of potential toxic targets, there were 78 key targets such as TP53, INS, IL6, AGT, ADCY3, and so on. Enrichment analysis of the top module with 19 genes from module analysis indicated that T wilfordii might cause reproductive toxicity by gene ontology terms and KEGG pathways such as regulation of vasoconstriction, G-protein coupled receptor signaling pathway, inflammatory response, cAMP signaling pathway, and so on. In the network between effective compounds of T wilfordii and key targets, there were 5 compounds with high degree including Tingenone, Wilfordic Acid, Abruslactone A, Nobilin, and Wilforlide B. The complex molecular mechanism of reproductive toxicity of T wilfordii can be preliminarily elucidated with the help of the network pharmacology method, and the analysis results can provide some reference for the further mechanism research of reproductive toxicity of T wilfordii.


  • Open Access

    MicroRNA-146a suppresses rheumatoid arthritis fibroblast-like synoviocytes proliferation and inflammatory responses by inhibiting the TLR4/NF-kB signaling

    by Wei Liu, Yuan-Hao Wu, Lei Zhang, Bin Xue, Yi Wang, Bin Liu, Xiao-Ya Liu, Fang Zuo, Xiao-Yan Yang, Fu-Yu Chen, et al.

    MicroRNA-146a suppresses rheumatoid arthritis fibroblastlike synoviocytes proliferation and inflammatory responses by inhibiting the TLR4/NF-kB signaling MicroRNA-146a suppresses rheumatoid arthritis fibroblast-like synoviocytes proliferation and inflammatory responses by inhibiting the TLR4/NF-kB signaling


  • Open Access

    Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis

    by Wei Liu, Yuan-Hao Wu, Lei Zhang, Xiao-Ya Liu, Bin Xue, Bin Liu, Yi Wang, Yang Ji

    Ankylosing spondylitis (AS) is an inflammatory rheumatic disease with impact on axial skeleton, peripheral joints and enthuses, and it may result in severe disabilities of those parts. Tumor necrosis factor-α (TNF-α) inhibitors are considered as an effective treatment for patients with active AS. In this study, we conducted a network meta-analysis to compare the clinical outcomes of active AS patients treated with TNF-α inhibitors. Randomized controlled trials (RCTs) evaluating the efficacy and safety of TNF-α inhibitors were retrieved in literature search and selected for meta-analysis. Changes in ASAS20 response, ASAS40 response and BASDAI 50% response were regarded as efficacy outcomes; serious adverse events (SAE) and all cause withdrawals were regarded as safety outcomes. Both traditional pairwise meta-analysis and network meta-analysis were performed. The results showed that adalimumab and infliximab had better clinical outcomes. Infliximab consistently appeared to be the most effective TNF-α inhibitors with a high risk of adverse events for patients with active AS; meanwhile, adalimumab ranked highest with respect to adverse effects with efficacy secondary to infliximab. As a result, we were unable to conclude the optimal TNF-α inhibitor and this issue should be solved by future researchers.


  • Open Access

    A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Tong Luo Hua Shi capsule, a modernized Tibetan medicine, in patients with rheumatoid arthritis

    by Wei Liu, Yuan-Hao Wu, Si-Yuan Hu, Cheng-Liang Zhong, Ming-Li Gao, Dong-Wu Liu, Hai-Yun Wang, Mu-Zhi Chen, Yue-Jin Song, Ben-Zha-Xi Yang, et al.

    Tong Luo Hua Shi (TLHS) is a new formulation of the traditional Tibetan medicine Wu-wei-gan-lu that has been used for the treatment of rheumatoid arthritis (RA) for hundreds of years in China. This study aimed to evaluate the efficacy and safety of TLHS in patients with RA. This was a randomized, double-blind, placebo-controlled, dose-finding study performed in patients with active RA from five medical centers. Patients received three doses (4.8, 3.6, or 2.4 g/day po) of TLHS or placebo (tid po) for 8 weeks. Blood sampling, physical examination, and assessment of the American College of Rheumatology (ACR) 20 % improvement (ACR20) criteria were performed before and every 2 weeks after starting treatment. The primary endpoint was the ACR20. The secondary endpoints included safety. A total of 240 participants were screened and 236 patients were randomized (n = 59/group); 20 dropped out. After 8 weeks, ACR20 improvements in the TLHS 4.8 g and 3.6 g groups were significantly higher than in the placebo group (P < 0.01 and P < 0.05, respectively). ACR50 improvement in the TLHS 4.8 g group was significantly higher compared with the placebo group (P < 0.01). Symptoms of RA were significantly relieved in the TLHS groups. In the TLHS groups, insomnia (n = 1), gastroenteric reactions (n = 2), arrhythmia (n = 1), and minor hepatic lesion (n = 1) were reported; in the placebo group, hepatic dysfunction (n = 1) was reported (P = 0.878). TLHS improved the symptoms of patients with RA according to the ACR20. Moreover, TLHS was safe. Chinese Clinical Trial Registry: ChiCTR-TRC-12003871 . Registered on 1 January 2012.


    • 15 October 2015
      • Vol. 8  (10) , 17362-76

    Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis.

    by Wei Liu, Yuan-Hao Wu, Lei Zhang, Xiao-Ya Liu, Bin Xue, Yi Wang, Bin Liu, Qiao Jiang, Hou-Wen Kwang, Dong-Jing Wu

    A meta-analysis was undertaken to examine the correlation between ankylosing spondylitis (AS) progression and serum levels of pro-inflammatory cytokines, Interleukin-6 (IL-6) and Interleukin-17 (IL-17) in AS patients. PubMed, EBSCO, Cochrane Library database, Ovid, Springer link, WANFANG, China national knowledge infrastructure (CNKI) and VIP databases(last updated search in October, 2014) were exhaustively searched for published case-control studies using keywords related to IL-6, IL-17 and AS. The search results were screened using stringent inclusion and exclusion criteria, and the data from selected high-quality studies was analyzed with Comprehensive Meta-analysis 2.0 software. Thirteen case-control studies were selected for this meta-analysis and contained a pooled total of 514 AS patients and 358 healthy controls. Our main result revealed strikingly higher serum levels of IL-6 and IL-17 in AS patients, compared to healthy controls (IL-6: SMD = 2.51, 95% CI = 1.33~3.70, P = 0.01; IL-17: SMD = 3.05, 95% CI = 2.09~4.02, P < 0.001). Ethnicity-based subgroup analysis showed a statistically correlation of high IL-6 and IL-17 serum levels with AS both in Asian (IL-6: SMD = 3.15, 95% CI = 0.75~5.55, P < 0.001; IL-17: SMD = 3.30, 95% CI = 1.93~4.66, P < 0.001) and Caucasian populations (IL-6: SMD = 1.34, 95% CI = 0.33~2.35, P = 0.009; IL-17: SMD = 2.52, 95% CI = 1.06~3.98, P = 0.001). Meta-analysis of pooled data from thirteen high-quality studies revealed a strong correlation between elevated IL-6 and IL-17 serum levels and the development of AS. Therefore, IL-6 and IL-17 could be used as markers for diagnosis and assessment of treatment outcomes in AS patients.